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Abstract 
Skin lighteners and hair relaxers, both common among women of African descent, have been 
suggested as possibly affecting breast cancer risk. In Accra and Kumasi, Ghana, we collected 
detailed information on usage patterns of both exposures among 1,131 invasive breast cancer 
cases and 2,106 population-controls.  Multivariate analyses estimated odds ratios (OR) and 95% 
confidence intervals (CIs) after adjustment for breast cancer risk factors. Control usage was 
25.8% for ever use of skin lighteners and 90.0% for use of hair relaxers for >1 year.  The OR for 
skin lighteners was 1.10 (95% CI 0.93-1.32), with higher risks for former (1.21, 0.98-1.50) than 
current (0.96, 0.74-1.24) users.  No significant dose-response relations were seen by duration, 
age at first or frequency of use.  In contrast, an OR of 1.58 (95% CI 1.15-2.18) was associated 
with hair relaxers, with higher risks for former (2.22, 1.56-3.16) than current (1.39, 1.00-1.93) 
users.  Although numbers of burns were inconsistently related to risk, associations increased with 
duration of use, restricted to women who predominately used non-lye products (p for 
trend<0.01).  This was most pronounce  among women with few children and those with 
smaller tumors, suggesting a possible role for other unmeasured lifestyle factors. This study does 
not implicate a substantial role for skin lighteners as breast cancer risk factors, but the findings 
regarding hair relaxers were less reassuring. The effects of skin lighteners and hair relaxers on 
breast cancer should continue to be monitored, especially given some biologic plausibility for 
their affecting risk. 
 
Keywords:  Breast cancer, skin lighteners, hair relaxers, etiology, African women 
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Summary: Although skin lighteners were unrelated to breast cancer, hair relaxer findings were 
less reassuring, with elevated risks seen for former and long-duration users of non-lye products. 
The extent to which this was due to biology, chance or confounding is unclear.   
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Introduction 
Much recent attention has focused on rising rates of breast cancer across Africa (1), with 
estimates that there will be an approximate doubling in the numbers between 2012 and 2030 (2). 
The increases will be particularly profound for younger women, where it is estimated that the 
number of breast cancer cases among women less than 65 years of age will increase from 
111,169 to 186,012.  Despite this dramatic anticipated increase, few epidemiologic studies have 
attempted to identify reasons for rising rates.  Previous studies suggest that a substantial 
proportion of disease occurrence may be due to an increased prevalence of factors responsible 
for breast cancers in other parts of the world, including decreasing parity, later ages at first 
childbirth, and increasing body sizes (3).  However, it remains unclear whether other unique 
factors could contribute to breast cancers among African women. 
 Several lifestyle characteristics of Africans and African Americans possibly involved in 
the etiology of breast cancers have recently come under scrutiny (4).  These include the use of 
skin lighteners (5-7) and hair relaxers (8, 9), both extremely common practices among women of 
African descent.  Skin lighteners are composed of a variety of substances, including topical 
steroids, mercury, and hydroquinones (10).  They may also contain hormonally active 
compounds, such as phthalates (11), which are often reported under the terms ‘fragrances’ or 
‘perfumes’ (12), and are rarely regulated, even in the U.S. (13). 
Hair relaxers are generally classified as being either lye or non-lye, with lye relaxers 
comprised of sodium hydroxide and non-lye relaxers comprised of potassium hydroxide, lithium 
hydroxide, guanidine carbonate, or ammonium thioglycolate (thio-relaxers) (9).  These products 
can also contain hormonally active compounds, such as phthalates (14) as well as other 
contaminants, including formaldehyde (15) and various metals (16, 17).  Given that hair relaxers 
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can cause burns and lesions in the scalp (18), concern has been expressed over the ability of their 
constituents to systemically spread and affect other organs, including the breast. 
 It is recognized that breast cancers occurring among women of African descent tend to 
have unique clinical characteristics, being diagnosed at earlier ages than Caucasians and more 
often having poor prognostic factors, including hormone receptor negativity (1).  Whether 
lifestyle characteristics, such as use of skin lighteners and hair relaxers, are associated with these 
unique characteristics has not yet been assessed in any epidemiologic study. 
 To shed further light on the relationship of skin lighteners and hair relaxers on breast 
cancers among African women, we used data from the Ghana Breast Health Study, a recently 
completed population-based case-control study conducted in two large metropolitan areas.  
Women were asked detailed questions regarding their use of both practices, including ages at 
first use, frequency of use, types of products used, and, for hair relaxers, how often scalp burns 
were experienced.  These parameters were evaluated in relation to the overall development of 
breast cancers as well as to specific breast cancers which predominate among African women 
(e.g., early onset and advanced tumors). 
 
Methods 
 To elaborate the effects of skin lighteners and hair relaxers as well as other factors on 
breast cancer risk, we conducted a multi-disciplinary population-based case-control study in two 
areas of Ghana, Accra and Kumasi.  The methodology of this investigation is described in more 
detail elsewhere (3).  In brief, patients for the study were recruited at the time they presented 
with lesions suspicious of breast cancer at three hospitals:  Korle Bu Teaching Hospital (Accra), 
Komfo Anoyke Teaching Hospital (Kumasi), and Peace and Love Hospital (Kumasi).  These 
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hospitals are the primary providers of treatment for breast cancer in Ghana, allowing for cases in 
our study to represent the vast majority of breast cancers diagnosed in these areas during the 
study period.  Cases for this study comprised women aged 18-74 years who were from defined 
catchment areas (chosen to be within restricted travel times from the study hospitals given that 
the study also involved the recruitment of population controls from their homes) who lived in 
these areas for at least one year and who were subsequently diagnosed with pathologically 
confirmed invasive breast cancers.  
A national census conducted in Ghana in 2010 enabled selection of population controls, 
who were frequency matched to the cases in the two study areas (Accra and Kumasi) on age, 
with similar restrictions regarding catchment areas and at least one year of residence in these 
areas.  The census was used to select enumeration areas (EA) (areas comprised of approximately 
750 residents) from the districts from which cases were expected to derive.  Trained census 
workers enumerated all households with respect to the sexes and ages of the residents.  When 
households were enumerated, a brochure was left explaining the study and encouraging 
participation should an individual be selected for inclusion.  After selected EAs had been 
enumerated, individuals were randomly selected to approximate the age distribution of female 
breast cancer cases expected during the study.  Study personnel visited subjects’ homes to 
determine eligibility, inform them of study selection, and invite them for a hospital visit. 
Both cases and controls were approached for in-person interviews by trained personnel 
who recorded information on standardized questionnaires.  Interviews were generally conducted 
in the hospitals, although a few were administered at the subjects’ homes.  Interview response 
rates were 99.2% in cases and 91.9% in controls.  A pathology review as well as genotyping 
efforts resulted in a few changes in eligibility status from the original methodology as described 
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previously (3), resulting in the inclusion in the present analysis of 1,131 invasive breast cancer 
cases and 2,106 controls.  
The questionnaire focused on established breast cancer risk factors (demographic factors, 
menstrual and reproductive characteristics, family history of breast cancer, medical history, 
occupational history, anthropometric and physical activity variables) as well as on several more 
speculative factors, including use of skin lighteners (any soap, cream or other product to lighten 
or brighten the skin) and hair relaxers (perms or other relaxers).  Subjects were asked whether 
they had ever used either product and, if so, the age at which they first began using them, 
currency of use, last usage (if a non-current user), and duration of use.  For skin lightener user, 
subjects were asked on which parts of the body creams were applied (all over, face, arms, chest, 
other parts) and how frequently products were applied.  For hair relaxers, women were asked to 
provide information on whether they generally used lye or non-lye products and how many times 
over their lives they had experienced burns (i.e., not just tingling but actual skin breakage).   
Following the interview, interviewers were requested to record the length of the interview 
and rate the patient’s extent of cooperation (very good, good, fair, poor) as well as the overall 
quality of the interview (high quality, generally reliable, questionable, unsatisfactory).  The 
median time to compl te an interview was 41 minutes in cases and 38 minutes in controls.  A 
total of 99.1% of the case interviews were deemed generally reliable or of high quality, as 
compared to 99.8 % of the control interviews. 
Odds ratios (OR) and 95% confidence intervals (CI) were calculated for various 
parameters of usage of skin lighteners and hair relaxers.  We adjusted for study site and age (as a 
categorical variable) as well as for the major identified risk factors in this study population, 
namely education, family history of breast cancer, body size, and parity.  Several risk factors 
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identified in other populations, such as usage of alcohol or menopausal hormone therapy, were 
infrequent in this population and unrelated to risk.  We calculated p values for differences 
between study groups as well as p values for linear trends. Tests for trend were constructed for 
categorizations of hair relaxer and skin lightener use using the continuous data, when applicable, 
or the mid-value in each level as a continuous covariate.  P-values from Wald F-tests were 
reported. We also assessed the extent to which associations with skin lighteners and hair relaxers 
varied across levels of identified risk factors, including age, education, and parity. Tests for 
interaction were assessed using log-likelihood test statistics (likelihood ratio test), where models 
with and without interaction terms were compared.  Associations by tumor size at the time of 
biopsy (< vs. > 5 cm.) were also assessed, with all risks calculated in reference to the total series 
of controls.  For all analyses, p-values <0.05 were considered statistically significant.  All 
statistical tests (p-values quoted) were two sided.  All analyses were performed using SAS 9.3 
(SAS Institute Inc., Cary, NC). 
 Finally, a number of sensitivity analyses were pursued, including using different referent 
groups for assessing the relation of hair relaxer use to risk given that the vast majority of women 
reported usage.  In addition, analyses were conducted that were restricted to interviews judged by 
interviewers to be of the highest quality (48.9% in cases, 48.8% in controls). 
 
Results 
 Cases were significantly older than controls with respect to age (mean ages in cases vs. 
controls of 50.1 vs. 45.6 years), reflecting that controls were frequency matched to the entire 
population of women with lesions suspicious for cancer, with many ultimately not being 
diagnosed with cancer (3).  Cases also tended to significantly more often to report higher levels 
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of education, family histories of breast cancer, larger body sizes, later ages at menarche, fewer 
children and later ages at first birth (Table 1). 
 Skin lightener use was quite common in this population, with 25.8% of the controls 
reporting ever use.  Hair relaxer use was reported by 93.4% of the controls.  Because of the high 
rates of hair relaxer use, we combined the never users with those who had used relaxers for less 
than or equal to one years’ time to derive a more stable referent.  This reduced the usage rate 
among controls to 90.0%.   
When these two practices were examined among the controls by various levels of 
identified risk factors (Table 2), we found that skin lightener use was significantly more common 
among older women (>45 years of age).  In addition, higher rates of usage were found among 
women with fewer years of educations and those who had their first child at a young age. Skin 
lightener use did not vary significantly by family histories of breast cancer, reported body sizes 
or ages at menarche. 
 Hair relaxer use was most frequently reported by women between the ages of 35 and 54 
years of age, with lower percentages among the youngest and oldest women in the study.  Usage 
was significantly more common among women who reported family histories of breast cancer, 
later ages at menarche, and multiple births.  Usage rates did not vary significantly by education 
or body sizes. 
 Ever use of skin lighteners was unrelated to breast cancer risk (OR=1.10, 95% CI 0.93-
1.32), with similar relations seen in Accra (1.26, 0.93-1.71) and Kumasi (1.02, 0.82-1.27) (Table 
3), despite the slightly higher rates of usage in controls in Kumasi compared to Accra (27.9% vs. 
22.0%).  Former users were at somewhat higher risk than current users (ORs and 95% CIs of 
1.21, 0.98-1.50 vs. 0.96, 0.74-1.24), a trend seen in both cities.  However, there were no 
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distinctive trends by length of use, age at first use, or frequency of use.  No further 
discrimination of risks was seen when these parameters were examined by currency of use (data 
not shown).  Risks were most elevated among those who reported first usage at ages 26-30 years 
(but not at earlier or later ages at first use) as well as those who reported usage once a day 
(OR=1.38, 95% CI 1.06-1.79), with no elevations seen for those reporting use on a more frequent 
basis.  These relations largely reflected elevated risks seen in Accra.  Most controls (90.5%) 
reported applying skin lighteners all over their bodies (data not shown).  There were a fair 
number of women who were unable to provide information regarding detailed usage patterns, 
and this category was often at significantly increased risk (e.g., OR for unknown age at first use 
was 1.56, 95% CI 1.02-2.41).  Elevated risks associated with unknown responses were observed 
more frequently in Kumasi than in Accra. 
 Ever use of hair straighteners was associated with a 58% increase in breast cancer risk 
(95% CI 1.15-2.18) (Table 4).  This association was mostly limited to an increased risk among 
patients in Accra (OR=2.31, 1.40-3.82), with no meaningful increase seen in Kumasi (1.22, 0.80-
1.88).   However, in both sites as well as overall, former users were at higher risks than current 
users and these risks were statistically significant (ORs and 95% CIs for both sites of 2.22, 1.56-
3.16 vs. 1.39, 1.00-1.93).  In Accra, there was a significant trend in risk with increasing length of 
use (p for trend<0.01) which was not observed in Kumasi (p for trend=0.26).  A number of 
subjects were unable to provide information on this parameter.  A higher risk was observed for 
use of non-lye compared to lye hair relaxers (ORs and 95% CIs for both sites of 1.88, 1.34-2.64 
vs. 1.38, 0.99-1.93), a trend seen in both Accra and Kumasi.  There was an approximate 70-80% 
increased risk seen both among subjects who had never experienced burning with hair relaxer 
use as well as among those with 5 or more lifetime burns, but this pattern of risk was observed 
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only in Accra.  In Kumasi, the number of episodes of burns was not significantly related to risk 
(p for trend=0.99) (Table 4). 
 When we classified currency of use, length of use and frequency of burns by whether the 
usual hair relaxer use was lye or non-lye (Table 5), we saw no association of any of these 
parameters of use among the lye users.  However, among the non-lye users, former users were at 
a significantly increased risk (OR=3.18, 95% CI 2.08-4.87) and there was a dose response 
relation with length of use (p for trend<0.01), increasing to a risk of 2.61 (1.65-4.10) among 
users of more than 30 years.  Similar statistically significant trends in risk with duration of use 
for non-lye users were seen in both Accra and Kumasi (Supplementary Table 1).  An especially 
pronounced risk was seen overall for former, long-duration users (OR=2.73, 95% CI 1.55-4.49) 
(data not shown).   
 An analysis of ever use of skin lighteners or hair relaxers by levels of identified risk 
factors in the study showed no significant heterogeneity by age (Table 6).  There was also no 
variation in skin lightener use by years of education, number of full-term pregnancies or by 
whether the tumor was <5 cm. or >5 cm. at the time of biopsy.  However, for hair relaxer use 
(among both lye and non-lye hair relaxer users), we did observe significant heterogeneity in 
relation to all three of these parameters, with stronger relations for women with primary/junior 
secondary school and those fewer births.  Cases with smaller tumors (<5 cm.) also showed 
stronger relations with both lye and non-lye hair relaxers use. 
 Given that few women had not used hair relaxers, we employed different referent groups 
to lead to more stable comparisons (expanding referent to include those with <5 or <10 years of 
use).  For instance, expanding our comparison group to include never users as well as those who 
had <5 years of use increased the referent group to 85 cases and 304 controls.  However, these 
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additional analyses had little impact on derived conclusions.  We also conducted analyses 
restricted to interviews that were deemed by the interviewers to be of the highest quality.  
Although we had fewer women with unknown responses for the detailed usage characteristics, 
our conclusions regarding the associations of hair relaxers to breast cancer risk remained 
unchanged. 
 
Discussion 
 Despite increasing incidence, little attention has focused on identifying risk factors for 
breast cancers in African women.  Several lifestyle factors have come under recent scrutiny, 
including the prevalent use of skin lighteners and hair relaxers, which both have constituents that 
raise concern.  We had the opportunity to evaluate both exposures in the present investigation as 
these practices were quite prevalent in Ghana.  Our results were generally reassuring regarding 
potential effects for skin lightener usage.  However, for hair relaxers, the results were more 
complicated to interpret, with some increases, particularly among users of non-lye products.   
 There has been increasing recent attention regarding cultural determinants of use of skin 
lighteners, which are believed to enhance beauty and lead to greater social privileges, including 
better jobs and marital prospects (6, 19).  As documented by a number of recent surveys (6, 20-
22), including one in Ghana (21), skin lightener use is quite prevalent, particularly in Africa.  In 
fact, in our study, we found usage occurring in approximately a quarter of our study subjects.  
These products were frequently used, oftentimes applied several times a day all over the body, 
with most subjects reporting many years of exposure. 
Skin lighteners are of particular concern with respect to breast cancer given that many 
contain steroids and hydroquinones, which since 2001 are no longer authorized for use in 
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cosmetic skin lightening in European Union countries (23).  Nonetheless, studies document that 
hydroquinones (5, 10, 24), as well as mercury (25, 26), are still quite prevalent in skin lightening 
products used in a variety of countries, including Africa.  Although hydroquinones, a primary 
metabolite of benzene, are not currently classified as carcinogenic to humans, there is recent 
evidence that it can have a variety of adverse topical and systemic repercussions, including 
hypopigmentation, ochronosis, changes in skin consistency, striae, and infections (19, 21).  
Hydroquinones (10, 23, 24) as well as mercury (25, 26) can also generate DNA damage and 
immunosuppressive responses.  In addition, a number of personal care products, including both 
skin lighteners and hair relaxers, commonly contain phthalates, which can be absorbed by the 
skin or inhaled (11, 27-29).  Phthalates have been shown to have estrogenic effects in cell (30) 
and animal (31) models, with some additional speculation that as endocrine disruptors they may 
act as human breast carcinogens (32, 33).   
We observed some increases in risk related to certain patterns of usage of skin lighteners, 
but the elevations were not consistent with meaningful biologic effects (e.g., highest risk only 
among subjects who used them once a day as opposed to more often).  Thus, it appeared that 
these risks were either chance findings or due to different selection biases.  We also observed 
some elevations among women who were unable to provide information on their precise usage 
patterns, a not surprising finding given the relatively low educational status of many of the 
subjects, which could have led to some of the anomalous significant elevations in risk that we 
observed.  Thus, our data in aggregate do not raise large concerns regarding the effects of skin 
lighteners on breast cancer risk among African women, despite their very common usage. 
Although there has been much attention on the relation of hair dyes to breast cancer risk, 
with the relationship remaining unresolved (34), only two previous epidemiologic studies have 
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assessed the relation of hair relaxers to breast cancer risk (35, 36).  In one investigation that 
focused on African-American women (36), there were no increases in risk associated with any 
categories of duration of hair relaxer use, frequency of use, age at first use, number of burns 
experienced during use, or type of relaxer used.  However, in that same investigation, an 
enhanced risk of uterine leiomyomas was observed in relation to hair relaxer use, with positive 
trends observed for frequency of use, duration of use, and number of burns (37), suggesting that 
these products could have harmful hormonal effects.  In contrast, in the most recent investigation 
on the relation of hair relaxers to breast cancer risk, that included both African-American and 
white women (35), use among white women was associated with significantly elevated breast 
cancer risks, particularly for estrogen receptor negative diseases.  No association with use, 
however, was seen among the African-American women in the study. 
Hair relaxers raise concern regarding breast cancer risk due to the burns they can cause, 
allowing systemic entry of hair relaxer constituents and effects on the immune system, which is 
increasingly being recognized as important in breast carcinogenesis (38, 39).  Although lye 
products have generally been regarded as more toxic than non-lye products, both have been 
associated with scalp inflammation and scarring alopecia (40). 
In our study, we observed significantly elevated risks associated with certain parameters 
of hair relaxer usage.  The elevated risks did not appear to relate to the number of episodes of 
burns, which has been hypothesized as a mechanism for systemic effects.  However, we 
observed evidence of elevated risks for former hair relaxer users and for users of non-lye 
products.  In addition, among the users of non-lye products, there were increasing trends with 
longer durations of use.  Although there were some differences in usage patterns as well as in 
associated risks between the two study sites, the elevated risks for former users and users of non-
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lye products were seen in both Accra and Kumasi, raising concern regarding a potential biologic 
relation of these products to breast cancer risk.   
Given that we had not hypothesized that we would observe higher risks associated with 
use of non-lye than lye products, the elevated risks that we observed for users of non-lye 
products must be cautiously interpreted.  The fact that we observed the highest risks among 
former and long-term users suggests that any association, if real, might have been driven by 
constituents that were part of hair relaxers marketed in the past.  Although recent attention has 
focused on effects of various endocrine disruptors, including phthalates (11) and lithium 
hydroxide (41), a potential carcinogenic role of various contaminants in hair products has also 
been recognized.  Although we did not have information on the constituents of the various hair 
products used, studies have noted detection of relatively high levels in hair relaxers of such 
contaminants as formaldehyde, arsenic, cadmium, as well as other metals (15, 42).  More recent 
evaluations of the levels of these elements in hair products seem to indicate more effective 
control of levels (43), possibly explaining why risks were higher in our study for former versus 
current users.    
Although a biologic relation at this point cannot be entirely dismissed, other explanations 
for our observed associations should also be considered.  For instance, the fact that the highest 
risks associated with hair relaxer use were seen only among women who were at elevated risks 
of breast cancer from well-established risk factors (e.g., decreased parity) suggests that the 
association may have been driven by other unmeasured factors.  Further, the association was 
strongest for women with smaller tumors, which we have previously demonstrated to relate to a 
variety of unique characteristics (44).  Nonetheless, we cannot dismiss a possible biologic 
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association of hair relaxer use with breast cancer risk and suggest that future studies continue to 
assess relations, particularly as related to specific constituents of the hair relaxers used. 
Our study has several strengths, including a large sample size and collection of detailed 
information on both the exposures of interest as well as other breast cancer predictors.  However, 
we were limited by the frequency at which information on detailed parameters of exposure, 
including durations of use and ages at first use, could not be provided.  More cases than controls 
could not provide this information; thus, if these women were less likely to have extensive 
exposures, our derived risks--particularly as related to long-duration non-lye hair relaxer use--
could be over-estimated.  Our results also might have been affected by the fact that we 
considered all breast cancers as a single entity, whereas substantial heterogeneity is well-
established, with risks varying by tumor subtypes (particularly those defined by hormone 
receptor status) (45).  Thus, molecular subtyping, which is currently ongoing in our 
investigation, will be important to further clarify our understanding of any etiologic variation. 
In summary, our results were reasonably reassuring regarding the effects of skin 
lighteners on breast cancer risk.  However, for hair relaxers, the findings were more complicated 
and indicated some increased risks associated with long-term usage for women who primarily 
used non-lye products.  Given that this was not the group that we had hypothesized would be at 
highest risk, it is difficult to discern the extent to which the findings are a reflection of 
confounding by other risk factors or of selection and reporting biases.  Given that the 
constituents of both skin lighteners and hair relaxers have biologic plausibility for exerting 
effects on cancer risk, it would seem worthwhile for these exposures to continue to be evaluated 
in future studies of women of African descent. 
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 Table 1. Characteristics of the Study Population 
  Controls  (N=2,106) Cases (N=1,131)   
  Number Percent Number Percent P-value 
Age 
    
<0.01 
     <35 435 20.7 114 10.1 
 
     35-44 561 26.6 278 24.6 
 
     45-54 554 26.3 332 29.4 
 
     55 or older 546 25.9 403 35.6 
 
     Unknown 10 0.5 4 0.4 
 
Education 
    
<0.01 
No formal education/some  
498 23.6 254 22.5 
          primary school 
     Primary school 369 17.5 153 13.5 
 
     Junior secondary school 654 31.1 262 23.2 
 
     >Senior secondary school 512 24.3 388 34.3 
 
     Unknown 73 3.5 74 6.54 
 
Family History of Breast Cancer 
    
<0.01 
     No 2036 96.7 1039 91.9 
 
     Yes 46 2.2 78 6.9 
 
     Unknown 24 1.1 14 1.2 
 
Body Size 
    
0.02 
     Slight 585 27.8 254 22.5 
 
     Average 827 39.3 434 38.4 
 
     Slightly heavy 470 22.3 263 23.3 
 
     Very heavy 163 7.7 104 9.2 
 
     Unknown 61 2.9 76 6.7 
 
Age at Menarche 
    
0.07 
     <15 568 27.0 268 23.7 
 
15 548 26.0 257 22.7 
 
16 383 18.2 223 19.7 
 
     >17 395 18.8 229 20.2 
 
     Unknown 212 10.1 154 13.6 
 
Number of Full-term Pregnancies 
    
<0.01 
     Nulliparous 228 10.8 107 9.5 
 
1 241 11.4 135 11.9 
 
     2-3 638 30.3 382 33.8 
 
     4-6 717 34.0 405 35.8 
 
     >7 274 13.0 98 8.7 
 
     Unknown 8 0.4 4 0.4 
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Age at First Full-term Pregnancy 
(Among Parous)     
<0.01 
     <19 555 29.6 236 23.0 
 
     19-21 510 27.2 266 26.0 
 
     22-24 303 16.1 200 19.5 
 
     25-27 213 11.3 123 12.0 
 
     >28 218 11.6 137 13.4 
 
     Unknown 79 4.21 62 6.05   
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Table 2. Use of Skin Lighteners and Hair Relaxers Among Controls by Identified Study Risk 
Factors 
  Use of Skin Lighteners
1
 Use of Hair Relaxers
2
 
 
No Yes P-
value 
No 
(N=186) 
Yes 
(N=1,681) 
P-
value (N=1,560) (N=542) 
Age 
  
<0.01 
  
<0.01 
     <35 82.7 17.3 
 
15.9 84.1 
 
     35-44 75.8 24.2 
 
6.9 93.1 
 
     45-54 69.4 30.6 
 
6.1 93.9 
 
     55 or older 70.6 29.4 
 
12.3 87.7 
 
Education 
  
<0.01 
  
0.34 
No formal education/  
74.1 25.9 
 
12.1 87.9 
    some primary school 
    Primary school 72.4 27.6 
 
9.8 90.2 
 
    Junior secondary school 70.9 29.1 
 
9.0 91.0 
 
>Senior secondary  
80.0 20.0 
 
9.0 91.0 
         school 
Family History of Breast 
Cancer   
0.14 
  
0.03 
     No 74.8 25.2 
 
10.1 89.9 
 
     Yes 65.2 34.8 
 
0.0 100.0 
 
Body Size 
  
0.07 
  
0.86 
     Slight 77.9 22.1 
 
9.1 90.9 
 
     Average 73.8 26.2 
 
10.6 89.4 
 
     Slightly heavy 72.3 27.7 
 
10.0 90.0 
 
     Very heavy 69.3 30.7 
 
10.1 89.9 
 
Age at Menarche 
  
0.18 
  
0.04 
     <15 71.5 28.5 
 
12.7 87.3 
 
15 75.0 25.0 
 
8.3 91.7 
 
16 77.3 22.7 
 
9.5 90.5 
 
     >17 72.2 27.8 
 
7.5 92.5 
 
Number of Full-term 
Pregnancies   
0.31 
  
0.01 
     Nulliparous 84.6 15.4 
 
23.8 76.2 
 
1 71.4 28.6 
 
13.8 86.2 
 
     2-3 75.3 24.7 
 
7.1 92.9 
 
     4-6 71.1 28.9 
 
6.8 93.2 
 
     >7 74.5 25.5 
 
9.9 90.1 
 
Age at First Full-term 
Pregnancy (Among   
<0.01 
  
0.48 
Downloaded from https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgy002/4792875
by Edinburgh University user
on 05 February 2018
Ac
ce
pte
d M
an
us
cri
pt
 
23 
 
Parous) 
     <19 68.5 31.5 
 
8.1 91.9 
 
     19-21 69.7 30.3 
 
8.4 91.6 
 
     22-24 78.2 21.8 
 
5.4 94.6 
 
     25-27 75.1 24.9 
 
9.5 90.5 
 
     >28 79.3 20.7 
 
8.9 91.1 
 
     Unknown 82.3 17.7   24.1 75.9   
1
Excludes 4 controls with missing information on skin lightener use. 
2
Excludes 239 controls with missing information on hair relaxer use. 
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Table 3.  Breast Cancer Risk by Various Parameters of Use of Skin Lighteners 
  All sites Accra Kumasi 
Skin Lightener 
Use 
Controls Cases OR
1
 95% CI Controls Cases OR
1
 95% CI Controls Cases OR
1
 95% CI 
                          
Ever Use 
            
     No 1560 818 1.00 Referent 571 280 1.00 Referent 989 538 1.00 Referent 
     Yes 542 307 1.10 
(0.93-
1.32) 
161 99 1.26 
(0.93-
1.71) 
381 208 1.02 (0.82-1.27) 
Currency of Use 
            
     Former 302 194 1.21 
(0.98-
1.50) 
92 67 1.44 
(1.00-
2.09) 
210 127 1.09 (0.84-1.42) 
     Current 240 113 0.96 
(0.74-
1.24) 
69 32 1.00 
(0.63-
1.59) 
171 81 0.92 (0.68-1.25) 
Length of Use 
(years)             
     <1  95 38 0.97 
(0.65-
1.45) 
36 15 0.92 
(0.48-
1.77) 
59 23 1.00 (0.59-1.68) 
     1-5 97 56 1.13 
(0.79-
1.62) 
19 17 2.07 
(1.01-
4.24) 
78 39 0.89 (0.58-1.35) 
     6-10 79 38 1.05 
(0.69-
1.59) 
17 12 1.81 
(0.82-
4.00) 
62 26 0.87 (0.53-1.43) 
     11-20 106 64 1.26 
(0.89-
1.77) 
22 17 1.43 
(0.73-
2.81) 
84 47 1.15 (0.77-1.71) 
     ≥21 100 52 0.85 
(0.59-
1.23) 
23 10 0.70 
(0.32-
1.54) 
77 42 0.88 (0.58-1.34) 
     Unknown 65 59 1.45 
(0.96-
2.18) 
44 28 1.27 
(0.72-
2.21) 
21 31 1.82 (0.97-3.40) 
P for trend 
  
0.96 
   
0.74 
   
0.69 
 
Age at First Use 
(years)             
     <21 180 82 0.96 
(0.72-
1.28) 
38 23 1.39 
(0.79-
2.45) 
142 59 0.83 (0.59-1.17) 
     21-25 113 55 0.96 
(0.68-
1.37) 
37 12 0.64 
(0.32-
1.29) 
76 43 1.10 (0.73-1.66) 
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     26-30 74 49 1.39 
(0.94-
2.06) 
19 16 2.14 
(1.04-
4.40) 
55 33 1.11 (0.69-1.80) 
     ≥31 118 67 1.04 
(0.75-
1.45) 
28 20 1.21 
(0.65-
2.27) 
90 47 0.96 (0.65-1.43) 
     Unknown 
57 54 1.56 
(1.02-
2.41) 
39 28 1.39 
(0.78-
2.46) 
18 26 1.87 (0.95-3.69) 
P for trend 
  
0.72 
   
0.36 
   
0.73 
 
Frequency of Use 
            
     Once per day 181 119 1.38 
(1.06-
1.79) 
50 42 1.93 
(1.22-
3.06) 
131 77 1.16 (0.84-1.60) 
     >2 times/day 332 160 0.97 
(0.78-
1.21) 
88 45 1.08 
(0.72-
1.62) 
244 115 0.90 (0.69-1.17) 
     Unknown 29 28 1.01 
(0.53-
1.90) 
23 12 0.63 
(0.27-
1.50) 
6 16 2.13 (0.72-6.27) 
P for trend     0.83       0.27       0.50   
1
All risks in referent to never users of skin lighteners (4 controls and 6 cases with unknown usage excluded).  Risks adjusted for age, 
study site, education, family history of breast cancer, body size, and parity.   
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Table 4.  Breast Cancer Risk by Various Parameters of Use of Hair Relaxers 
  All sites Accra Kumasi 
Hair Relaxer Use Controls Cases OR
1
 95% CI Controls Cases OR
1
 95% CI Controls Cases OR
1
 95% CI 
Ever Use 
            
     No
2
 186 58 1.00 Referent 93 23 1.00 Referent 93 353 1.00 Referent 
     Yes 1681 877 1.58 
(1.15-
2.18) 
485 269 2.31 
(1.40-
3.82) 
1196 608 1.22 
(0.80-
1.88) 
Currency of Use 
            
     Former 339 268 2.22 
(1.56-
3.16) 
117 97 3.12 
(1.79-
5.43) 
222 171 1.80 
(1.13-
2.88) 
     Current 1342 609 1.39 
(1.00-
1.93) 
368 172 2.01 
(1.20-
3.36) 
974 437 1.08 
(0.70-
1.67) 
Length of Use 
(years)             
     1-10 307 84 1.10 
(0.73-
1.64) 
86 21 1.46 
(0.72-
2.94) 
221 63 0.92 
(0.55-
1.54) 
     11-20 528 249 1.68 
(1.18-
2.40) 
145 69 2.38 
(1.34-
4.25) 
383 180 1.36 
(0.86-
2.17) 
     21-30 503 280 1.54 
(1.08-
2.20) 
139 76 2.02 
(1.14-
3.59) 
364 204 1.25 
(0.78-
1.99) 
     ≥31 295 218 1.67 
(1.15-
2.43) 
72 60 2.49 
(1.35-
4.62) 
223 158 1.35 
(0.83-
2.19) 
     Unknown 48 46 2.81 
(1.66-
4.77) 
43 43 3.73 
(1.94-
7.17) 
5 3 1.23 
(0.25-
6.04) 
     P for trend 
  
0.01 
   
<0.01 
   
0.26 
 
Age at First Use 
(years)             
     <21 1063 476 1.39 
(1.00-
1.94) 
280 116 1.84 
(1.08-
3.12) 
783 360 1.16 
(0.75-
1.80) 
     21-25 307 208 1.87 
(1.30-
2.69) 
101 71 2.78 
(1.56-
4.96) 
206 137 1.45 
(0.90-
2.34) 
     26-30 115 76 1.70 
(1.10-
2.64) 
32 19 2.12 
(0.98-
4.55) 
83 57 1.52 
(0.87-
2.63) 
     ≥31 150 69 1.38 
(0.89-
2.14) 
33 21 2.34 
(1.10-
4.98) 
117 48 1.04 
(0.60-
1.81) 
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     Unknown 
46 48 3.07 
(1.81-
5.21) 
39 42 3.91 
(2.02-
7.57) 
7 6 1.83 
(0.51-
6.66) 
P for trend 
  
0.05 
   
<0.01 
   
0.77 
 
Type of Hair 
Relaxer Most 
Frequently Used 
            
     Lye 998 472 1.38 
(0.99-
1.93) 
225 110 1.99 
(1.17-
3.39) 
773 362 1.10 
(0.71-
1.70) 
     Non-lye 655 385 1.88 
(1.34-
2.64) 
252 150 2.54 
(1.50-
4.28) 
403 235 1.55 
(0.98-
2.45) 
     Unknown 28 20 1.69 
(0.86-
3.30) 
8 9 4.65 
(1.57-
13.80) 
20 11 0.84 
(0.35-
2.00) 
Frequency of 
Burns (lifetime)             
Never had 
burns 
640 353 1.66 
(1.18-
2.34) 
139 90 2.52 
(1.45-
4.38) 
501 263 1.30 
(0.83-
2.04) 
     1-2 times 461 232 1.33 
(0.94-
1.90) 
152 75 2.06 
(1.18-
3.59) 
309 157 1.05 
(0.66-
1.67) 
     3-4 times 239 101 1.29 
(0.87-
1.92) 
79 23 1.28 
(0.65-
2.54) 
160 78 1.16 
(0.70-
1.94) 
     >5 times 288 139 1.76 
(1.20-
2.58) 
63 41 2.88 
(1.51-
5.48) 
225 98 1.29 
(0.79-
2.12) 
     Unknown 53 52 2.92 
(1.76-
4.86) 
52 40 3.27 
(1.72-
6.22) 
1 12 27.38 
(3.25-
230.75) 
     P for trend     0.45       0.32       0.99   
1
Risks adjusted for age, study site, education, family history of breast cancer, body size, and parity.   
2
All risks in referent to never users and users of <1 year of hair relaxers (58 cases, 186 controls). 
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Table 5. Breast Cancer Risk by Currency of Use, Length of Use or Frequency of Burns and 
Whether Usual Relaxer was Lye or Non-Lye 
  Lye Use Non-lye Use 
Hair Relaxer Most 
Commonly Used 
Exposed 
Cases 
  Exposed 
Cases 
  
OR
1
 95% CI OR
1
 95% CI 
       
Currency of Use
2
 
      
     Former 143 1.89 (1.28-2.79) 117 3.18 (2.08-4.87) 
     Current 329 1.20 (0.84-1.70) 268 1.76 (1.23-2.53) 
       
Length of Use
2
 (years) 
      
     1-10 46 1.16 (0.72-1.88) 37 1.24 (0.74-2.07) 
     11-20  144 1.71 (1.15-2.55) 100 1.79 (1.17-2.75) 
     21-30 144 1.18 (0.79-1.75) 128 2.14 (1.41-3.26) 
     ≥31 118 1.18 (0.77-1.80) 97 2.61 (1.65-4.10) 
     Unknown 20 2.25 (1.11-4.55) 23 4.07 (2.00-8.28) 
     P for trend 
 
0.95 
  
<0.01 
 
       
Frequency of Burns
2
 
(lifetime)       
     Never had burns 202 1.51 (1.04-2.18) 144 1.97 (1.33-2.93) 
     1-2 times 143 1.14 (0.77-1.67) 85 1.93 (1.25-2.98) 
     3-4 times 50 1.13 (0.71-1.82) 48 1.60 (0.97-2.64) 
     >5 times     59 1.40 (0.88-2.21) 76 2.23 (1.42-3.50) 
     Unknown 18 3.18 (1.45-6.99) 32 3.21 (1.76-5.86) 
     P for trend   0.63     0.60   
1
Risks adjusted for age, study site, education, family history of breast cancer, body size, and 
parity.   
2
All risks in referent to never users and users of <1 year of hair relaxers (58 cases, 186 controls).   
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Table 6.  Breast Cancer Risk by Skin Lightener and Hair Relaxer Usage by Other Demographic and Clinical Characteristics 
  Skin Lightener Use Lye Hair Relaxer Use Non-Lye Hair Relaxer Use 
Demographic and 
Clinical 
Characteristics 
Exp 
Cases 
OR
1
 95% CI Phet 
Exp 
Cases 
OR
1
 95% CI Phet 
Exp 
Cases 
OR
1
 95% CI Phet 
             
 Age 
   
0.70 
   
0.53 
   
0.73 
     <45 84 1.07 (0.79-1.45) 
 
181 1.54 (0.88-2.68) 
 
143 2.04 (1.16-3.61) 
 
     45-54 99 1.02 (0.74-1.41) 
 
129 1.16 (0.53-2.55) 
 
122 1.75 (0.80-3.85) 
 
     >55 123 1.26 (0.93-1.72) 
 
162 1.25 (0.72-2.17) 
 
118 2.05 (1.13-3.71) 
 
Education 
   
0.52 
   
0.01 
   
0.04 
No formal 
education/some  116 1.15 (0.87-1.52) 
 
169 1.01 (0.64-1.61) 
 
133 1.82 (1.11-2.99) 
 
primary school 
Primary/Junior 
secondary school 
86 1.17 (0.84-1.64) 
 
124 4.53 (1.53-13.47) 
 
99 5.30 (1.77-15.90) 
 
>Senior 
secondary school 
79 0.89 (0.62-1.27) 
 
177 1.29 (0.67-2.48) 
 
151 1.64 (0.86-3.14) 
 
Number of full-term 
Pregnancies    
0.98 
   
<0.01 
   
<0.01 
     0-1 63 1.10 (0.73-1.66) 
 
102 3.47 (1.57-7.70) 
 
88 6.46 (2.78-14.99) 
 
     2-3 99 1.03 (0.75-1.41) 
 
170 1.56 (0.79-3.07) 
 
133 1.87 (0.93-3.75) 
 
     >4 145 1.20 (0.93-1.55) 
 
200 0.85 (0.52-1.38) 
 
164 1.28 (0.77-2.13) 
 
Tumor Size 
            
     <5 cm. 102 1.02 (0.78-1.34) 
 
169 2.06 (1.04-4.11) 
 
138 3.01 (1.48-6.11) 
 
     >5 cm. 169 1.13 (0.91-1.40)   253 0.95 (0.64-1.41)   202 1.54 (1.02-2.31)   
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1
All risks in referent to never users or users of hair relaxers for <1 year.  Risks adjusted for age, study site, education, family history of 
breast cancer, body size, and parity. 
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